Latest Conference Articles

Artificial intelligence could be the future of detecting certain diseases in the eye, after a study presented at ASRS 2019 found that the EyeArt system was effective in detecting referable diabetic retinopathy from images.

Investigators presented 36-month results of a study which found that treatment with a single intravitreal injection of the FAi provided anti-inflammatory treatment for 3 years in patients with non-infectious uveitis affecting the posterior segment of the eye

Additional analyses of the phase 2 BOULEVARD trial, which found faricimab not only led to improved best-corrected visual acuity and central subfield thickness from baseline, but also provided anatomical benefits and displayed a potential for extended durability compared to anti-VEGF monotherapy, were presented during ASRS 2019

Medical Director of the Macular Degeneration Association discusses how the evolution of anti-VEGF treatments has changed the landscape of AMD care and the lives of patients.

Results of a study presented at ASRS 2019 found that biweekly anti-VEGF dosing may be an effective treatment for treating nAMD refractory to standard monthly dosing.

While often seen in a negative light, some physicians have found ways to incorporate electronic medical records to improve their practice.

Eleonora Lad, MD, PhD, presented results of a post-hoc analysis evaluating the impact of baseline characteristics on lesion progression in patients receiving APL-2 for geographic atrophy at ASRS 2019.

Carl Regillo, MD, of Wills Eye, and Michael Stewart, of the Mayo Clinic, discuss changes they would like to see in their speciality at ASRS 2019.

W. Lloyd Clark, MD, of Palmetto Retina Center, discusses clinical implications of the 52-week PANORAMA results, which found treatment with intravitreal aflibercept injections could reverse disease progression in patients with moderately severe to severe NPDR.

Early treatment and completing treatments key to visual acuity improvements in neovasculare age-related macular degeneration.

Ajay Kuriyan, MD, discusses what he warns patients to be aware of when seeking out treatment from stem cell therapies and why he believes other physicians should as well.

LADDER study results presented at ASRS revealed efficacy of the PDS was equal to that of monthly ranibizumab.

An oral therapy for aged-related macular degeneration could be on the horizon after displaying efficacy in a recent phase 2 study.

Carl Regillo, MD, who presented 96-week data of brolucizumab at ASRS 2019, discusses how brolucizumab could impact care of wAMD in a real-world setting.

More patients undergoing long-term use anti-VEGF therapy saw improvements in visual acuity than saw declines after 10 years.

Investigators from Wills Eye and Retina Consultants of Austin presented 96-week data from the HAWK and HARRIER trials at ASRS 2019.

Peter Kaiser, MD, presented data from a phase 2 trial examining the safety and efficacy of risuteganib at ASRS 2019.

W. Lloyd Clark, MD, discusses the approaches he uses in his clinical practice to reduce patient noncompliance — specifically, when treating diabetic macular edema.

As physician burnout becomes a more common issue, physician across an array of fields find themselves discussing and formulating ways to circumvent burnout.

Physician from Palmetto Retina Center on deciding between aflibercept, ranibizumab, and avastin for treatment of DME.

Here's a primer for new data and discussions MD Mag will be covering this weekend in Chicago.

Kodiak's KSI-301 was shown to have sustained benefit and safety in a phase 1a study involving patients with severe DME.

After Janssen's submission of an sNDA in March, results of the CREDENCE subgroup analyses were among the most anticipated presentations at ADA 2019.

A study presented at ADA 2019 examined the efficacy of sitagliptin compared with dapagliflozin in t2d patients 65 years old and older.

A 6-month study examining the effects of hepatic-directed prandial insulin in patients with type 1 diabetes mellitus was presented at ADA 2019.

Osama Hamdy, MD, PhD, discusses the impact of a 10-year study observing the impact of lifestyle interventions among diabetes patients in real-world clinical practice.

Investigators presented results of a study that analyzed renal function and markers of kidney damage in more than 1,000 patients in two randomized trials examining ertugliflozin.

A study analyzing the renal outcomes of the DECLARE-TIMI 58 trial were presented at ADA 2019 in San Francisco, CA.